论文部分内容阅读
目的:探讨低分子肝素治疗急性冠脉综合征(ACS)的临床疗效。方法:117例ACS患者随机分为观察组59和对照组58例,对照组给予阿司匹林、硝酸甘油、β-受体阻滞剂、钙拮抗剂等综合治疗;观察组在对照组基础上加用低分子肝素钠5 000 IU,脐周皮下注射,每隔12 h 1次,疗程1周。结果:观察组总有效率为94.9%,对照组总有效率为77.6%,两组比较差异有统计学意义(P<0.05)。观察组出院后1个月内再发心绞痛2例;对照组再发心绞痛3例,再发急性心肌梗死1例。结论:低分子肝素治疗急性冠脉综合征安全有效,值得推广。
Objective: To investigate the clinical effect of low molecular weight heparin in the treatment of acute coronary syndrome (ACS). Methods: A total of 117 patients with ACS were randomly divided into observation group 59 and control group 58. The control group was given aspirin, nitroglycerin, β-blockers and calcium antagonists. The observation group was added on the basis of the control group Low molecular weight heparin 5 000 IU, umbilical subcutaneous injection, once every 12 h, course of treatment for 1 week. Results: The total effective rate was 94.9% in the observation group and 77.6% in the control group, with significant difference between the two groups (P <0.05). In the observation group, 2 cases of recurrent angina were found within 1 month after discharge; 3 cases of recurrent angina in the control group and 1 case of recurrent acute myocardial infarction. Conclusion: Low molecular weight heparin is safe and effective in the treatment of acute coronary syndrome and is worth promoting.